ly3537982
eli lilly
['ly3537982', 'solid tumor']
today at #aacr23, will present results of a first-in-human phase 1 study of ly3537982 a highly selective #kras g12c inhibitor in people with advanced solid tumors with this mutation at 2:35 in the chaplin theater. 
The official account of @MSKCancerCenter’s Department of Medicine. Chair/Dept. Head: @debschrag